|
Uniparental disomy, paternal, chromosome 14
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Although recent studies in patients with paternal uniparental disomy 14 [upd(14)pat] and other conditions affecting the chromosome 14q32.2 imprinted region have successfully identified underlying epigenetic factors involved in the development of upd(14)pat phenotype, several matters, including regulatory mechanism(s) for RTL1 expression, imprinting status of DIO3 and placental histological characteristics, remain to be elucidated.
|
22917972 |
2012 |
|
Uniparental disomy, paternal, chromosome 14
|
0.310 |
ChromosomalRearrangement
|
disease |
ORPHANET |
Deletions and epimutations affecting the human 14q32.2 imprinted region in individuals with paternal and maternal upd(14)-like phenotypes.
|
18176563 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Shave biopsy and immunohistochemical studies revealed that the tumor was composed of malignant melanoma (MM) (highlighted by S100 and MART-1) intermixed with squamous cell carcinoma (SCC) (highlighted by cytokeratin and p63), and a diagnosis of combined MM-SCC was rendered.
|
31361351 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Shave biopsy and immunohistochemical studies revealed that the tumor was composed of malignant melanoma (MM) (highlighted by S100 and MART-1) intermixed with squamous cell carcinoma (SCC) (highlighted by cytokeratin and p63), and a diagnosis of combined MM-SCC was rendered.
|
31361351 |
2020 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.
|
30520800 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A retrospective cohort study evaluated 123 melanomas excised using MMS with MART-1 immunostain.
|
30199430 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, subcutaneous immunization of C57BL/6J mice with DCs ex vivo transfected with an electrostatic complex of AuNPs-SL & melanoma antigen (MART1) encoded DNA vaccine (p-CMV-MART1) induced a long lasting (100 days) anti-tumor immune response in immunized mice upon subsequent challenge with a lethal dose of melanoma.
|
30964937 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The CD44 expression correlated to PD-L1, but not to MART-1 expression in malignant melanoma.
|
31741714 |
2019 |
|
Age at menarche
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with melanoma who enrolled in the F5-MART-1 clinical trial (NCT00910650) received infusions of MART-1 T-cell receptors transgenic T cells with MART-1 peptide-pulsed dendritic cell vaccination.
|
29470191 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate using human melanoma cell lines that this resistance phenotype can be induced <i>in vitro</i> by treatment with MART1 T cell receptor-expressing T cells or with TNFα, and that the phenotype is reversible with withdrawal of inflammatory stimuli.
|
29899062 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
One paraffin-embedded section of the patients' primary melanoma (n = 60), relapse (n = 21), and naevus (n = 17) were immunohistochemically double-stained for Ki-67/MART1 and single-stained for CD271, CD166, and CD20.
|
29678478 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results show that SOX10 is more specific than MART-1 in distinguishing epidermal melanocytes on sun-damaged skin by avoiding overdiagnosis of melanoma.
|
29377259 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1.
|
29933102 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After an initial period of tumor regression, the patient presented in relapse with tumors lacking melanocytic antigens (MART1, gp100) and expressing an inflammation-induced neural crest marker (NGFR).
|
29899062 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The data demonstrate that tumor number in lnc-HUR1 transgenic mice is higher compared with control mice, indicating that lnc-HUR1 enhances diethylnitrosamine-induced tumorigenesis.
|
29790592 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This work evaluated the impact of surface modifications of mannosamine-conjugated multifunctional poly(glutamic acid) (PG)-dendrimers as nanocarriers of the tumour associated antigens (TAA) MART-1, gp100:44 and gp100:209.
|
28795601 |
2018 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In 2013, an axillary mass was excised to show metastatic melanoma with 2 morphologies: an epithelioid morphology expressing S100 and MART-1 and a spindled morphology with loss of melanocytic markers but strong expression of desmin.
|
29405341 |
2018 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This supports the hypothesis that acquired resistance to cancer immunotherapy can be mediated by inflammation-induced cancer dedifferentiation.<b>Significance:</b> We report a patient whose metastatic melanoma underwent inflammation-induced dedifferentiation as a resistance mechanism to ACT to the MART1 antigen.
|
29899062 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this paper, we propose a technique for measuring melanoma DoI in microscopic images digitized from MART1 (i.e., meleanoma-associated antigen recognized by T cells) stained skin histopathological sections.The technique consists of four modules.
|
28346884 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RTL1 promotes melanoma proliferation by regulating Wnt/β-catenin signalling.
|
29285312 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MART1, a human melanoma-specific tumor antigen, was used to induce an increased immune reaction, since a MART1-protective response is required to overcome immune tolerance to the melanoma antigen MelanA.
|
28178658 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because of the small round blue cell morphology and negative immunohistochemical staining for pan-melanocytic cocktail (HMB45, anti MART1 and anti-tyrosinase) and SOX10 in both cases, FLI-1 immunostaining was requested as part of the tumors workup.
|
28605142 |
2017 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NFATc2(+/Hi) melanoma cell lines were CD271(+) and deficient for expression of melanocyte differentiation antigens (MDAs) MART-1, gp100, tyrosinase and of GPNMB, PGC1-α and Rab27a, all regulated by MITF.
|
26387540 |
2016 |